SCHEMBL6413346

SCHEMBL6413346

Nc1nc2nonc2nc1NN=Cc1ccc(O)cc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 11/20 0.52
MAPT P10636 9/20 0.52
KDM4E B2RXH2 7/20 0.52
POLB P06746 7/20 0.52
HTT P42858 5/20 0.52
RAB9A P51151 4/20 0.52
NPC1 O15118 4/20 0.52
TDP1 Q9NUW8 4/20 0.52
L3MBTL1 Q9Y468 4/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 13/20 0.51
KMT2A Q03164 13/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 4/20 0.51
LMNA P02545 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
PKM P14618 1/20 0.51
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436307 0.88 GAA (0.58) GAAMAPTKDM4EPOLBHTT
SCHEMBL6436303 0.88 GAA (0.58) GAAMAPTKDM4EPOLBHTT
SCHEMBL6414918 0.81 DDX3X (0.63) GAAMAPTKDM4EPOLBHTT
SCHEMBL6436153 0.81 KMT2A (0.42) GAAMAPTKDM4EPOLBHTT
SCHEMBL6436156 0.81 KMT2A (0.42) GAAMAPTKDM4EPOLBHTT
SCHEMBL6417232 0.80 DDX3X (0.49) GAAMAPTKDM4EPOLBHTT
SCHEMBL6415725 0.79 GAA (0.51) GAAMAPTKDM4EPOLBHTT
SCHEMBL6422141 0.78 GAA (0.55) GAAMAPTKDM4EPOLBHTT
SCHEMBL6422145 0.78 GAA (0.55) GAAMAPTKDM4EPOLBHTT
SCHEMBL6416491 0.78 MEN1 (0.49) GAAMAPTKDM4EPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 GAA 3186/4885MAPT 4420/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.